Pyxis’s $152m Series B Will Push Trio Of ADCs Toward Clinic

Pyxis says its three preclinical ADCs, acquired from Pfizer and LegoChem, offer immunomodulatory effects as well as direct killing of tumor cells. It hopes all three will reach Phase I in 2022.